We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Panel Supports J&J’s Remicade for Pediatric Ulcerative Colitis
FDA Panel Supports J&J’s Remicade for Pediatric Ulcerative Colitis
July 29, 2011
An FDA advisory committee has voted in favor of expanding use of Johnson & Johnson’s (J&J) Remicade to pediatric patients with ulcerative colitis (UC) but says more data is needed to determine the drug’s long-term effects.